A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA

Cancer Letters

Volumn 365, Issue 2, 2015, Pages 156-165

  Zhang, Tingting ^a,b   Xue, Xiang ^a   He, Dalin ^b,c   Hsieh, Jer Tsong ^d  

^a THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

MicroRNA; Polyplex; Prostate cancer; R11 peptide

Indexed keywords

ARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGININE; BMI1 PROTEIN; MICRORNA 145; POLYARGININE; POLYETHYLENEIMINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG; DRUG CARRIER; MICRORNA; MIRN145 MICRORNA, HUMAN; NANOPARTICLE; PEPTIDE; TUMOR MARKER;

AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BIOCOMPATIBILITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DRUG SPECIFICITY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; RNA TRANSLATION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; PERITONEAL NEOPLASMS; PROCEDURES; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG CARRIERS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE; MICRORNAS; NANOPARTICLES; PEPTIDES; PERITONEAL NEOPLASMS; PROSTATIC NEOPLASMS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84937640198     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.05.003     Document Type: Article

References (27)

1. Balistreri C.R., Candore G., Lio D., Carruba G. Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments. Cancer Gene Ther 2014, 21:2-11.
2. Francini E., Petrioli R., Rossi G., Laera L., Roviello G. PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials. Tumour Biol 2014, 35:10601-10607.
3. Barbato C., Ruberti F., Cogoni C. Searching for MIND: microRNAs in neurodegenerative diseases. J. Biomed. Biotechnol 2009, 2009:871313.
4. Hwang do W., Son S., Jang J., Youn H., Lee S., Lee D., et al. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 2011, 32:4968-4975.
5. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:7297-7301.
6. Aigner A., Fischer D., Merdan T., Brus C., Kissel T., Czubayko F. Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther 2002, 9:1700-1707.
7. Fountaine T.M., Wood M.J., Wade-Martins R. Delivering RNA interference to the mammalian brain. Curr. Gene Ther 2005, 5:399-410.
8. Zintchenko A., Philipp A., Dehshahri A., Wagner E. Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity. Bioconjug. Chem 2008, 19:1448-1455.
9. Fischer D., Bieber T., Li Y., Elsasser H.P., Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm. Res 1999, 16:1273-1279.
10. Lee S.J., Huh M.S., Lee S.Y., Min S., Lee S., Koo H., et al. Tumor-homing poly-siRNA/glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment. Angew. Chem. Int. Ed Engl 2012, 51:7203-7207.
11. Son S., Hwang do W., Singha K., Jeong J.H., Park T.G., Lee D.S., et al. RVG peptide tethered bioreducible polyethylenimine for gene delivery to brain. J. Control. Release 2011, 155:18-25.
12. El-Andaloussi S., Holm T., Langel U. Cell-penetrating peptides: mechanisms and applications. Curr. Pharm. Des 2005, 11:3597-3611.
13. Gupta B., Levchenko T.S., Torchilin V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev 2005, 57:637-651.
14. Wadia J.S., Dowdy S.F. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Rev 2005, 57:579-596.
15. Hsieh J.-T., Zhou J., Gore C., Zimmern P. R11, a novel cell-permeable peptide, as an intravesical delivery vehicle. BJU Int 2011, 108:1666-1671.
16. Kumar P., Wu H., McBride J.L., Jung K.E., Kim M.H., Davidson B.L., et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007, 448:39-43.
17. Sachdeva M., Mo Y.Y. miR-145-mediated suppression of cell growth, invasion and metastasis. Am. J. Transl. Res 2010, 2:170-180.
18. Cho W.C., Chow A.S., Au J.S. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur. J. Cancer 2009, 45:2197-2206.
19. Fuse M., Nohata N., Kojima S., Sakamoto S., Chiyomaru T., Kawakami K., et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int. J. Oncol 2011, 38:1093-1101.
20. Shao Y., Qu Y., Dang S., Yao B., Ji M. MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer Cell Int 2013, 13:51.
21. Khan S., Ebeling M.C., Zaman M.S., Sikander M., Yallapu M.M., Chauhan N., et al. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget 2014, 5:7599-7609.
22. Zhu Z., Xu T., Wang L., Wang X., Zhong S., Xu C., et al. MicroRNA-145 directly targets the insulin-like growth factor receptor I in human bladder cancer cells. FEBS Lett 2014, 588:3180-3185.
23. Liu D.F., Wu J.T., Wang J.M., Liu Q.Z., Gao Z.L., Liu Y.X. MicroRNA expression profile analysis reveals diagnostic biomarker for human prostate cancer. Asian Pac. J. Cancer Prev 2012, 13:3313-3317.
24. Avgeris M., Stravodimos K., Fragoulis E.G., Scorilas A. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br. J. Cancer 2013, 108:2573-2581.
25. Huang S., Guo W., Tang Y., Ren D., Zou X., Peng X. miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol. Rep 2012, 28:1831-1837.
26. Wang J., Yu Y., Yan Z., Hu Z., Li L., Li J., et al. Anticancer activity of oncolytic adenoviruses carrying p53 is augmented by 11R in gallbladder cancer cell lines in vitro and in vivo. Oncol. Rep 2013, 30:833-841.
27. Wadajkar A.S., Menon J.U., Tsai Y.S., Gore C., Dobin T., Gandee L., et al. Prostate cancer-specific thermo-responsive polymer-coated iron oxide nanoparticles. Biomaterials 2013, 34:3618-3625.